Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SOTIO has acquired the rights to Unum Therapeutics’ BOXR cell therapy platform and BOXR lead programs to develop novel T cell therapies for the treatment of solid tumors.
Lead Product(s): BOXR1030
Therapeutic Area: Oncology Product Name: BOXR1030
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sotio
Deal Size: $11.5 million Upfront Cash: $8.1 million
Deal Type: Acquisition August 31, 2020
Details:
Acquisition includes lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor.
Lead Product(s): Bezuclastinib,Sunitinib
Therapeutic Area: Oncology Product Name: PLX9486
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Kiq
Deal Size: $104.4 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 06, 2020
Details:
Unum has initiated formal preclinical development activities, including preclinical safety testing and GMP process development, to support filing an IND application for BOXR1030 in late 2020.
Lead Product(s): BOXR1030
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2020
Details:
Cohort 1 recruitment is complete with no dose-limiting toxicity reported in the ATTCK-34-01 Phase 1 trial testing Unum's novel ACTR707 antibody-coupled T cell receptor investigational therapy with trastuzumab.
Lead Product(s): ACTR707,Trastuzumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020